Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

16 Apr 2009 08:49

RNS Number : 6591Q
ViaLogy PLC
16 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY BEGINS DRILLING SECOND WELL AT TEXAS PROSPECT

Analysis started on third, deeper well

LondonApril 16th 2009ViaLogy PLC (LSE:VIY) announces that a rig has been sited on Atascosa Exploration LLC's Galba Prospect in south central Texas using QuantumRD™, ViaLogy's proprietary active signal processing technology that brings greater accuracy to seismic data analysis. Deployment of the rig and drilling of a second well is expected to start immediately. QuantumRD's processing and interpretation of site-specific 3D seismic data has determined optimal drill location, reservoir boundaries, hydrocarbon porosity, and other parameters for the new well. Results should be available within a week following drilling start. Under its contract with Atascosa ViaLogy is to receive 5% Back-In- After-Payout (BIAPO) Working Interest on oil production from the well.

 

This second project follows the successful QuantumRD positioning in March 2009 of a first well at Galba, named Cindy Bartlett #2.

ViaLogy also announces that it has commenced a QuantumRD analysis to determine the exact reservoir characteristics, porosity, and optimal extraction location for a third well on the Galba Prospect, this one in the Escondido sand formation. At considerably greater depth than its predecessors, the Escondido well should demonstrate QuantumRD's applicability for varying geologic formations at increasing depths and complex structural characteristics. Drilling on the Escondido well is planned for Q2 2009. 

Further, Vialogy announces that it has begun technical and business discussions with a large Texas-based exploration and production firm to apply its QuantumRD technology to that firm's exploration prospects. 

"QuantumRD's accurate predictions of reservoir boundaries and porosities on the Cindy Bartlett #2 well have confirmed our belief, shared by Atascosa, that we can substantially improve the current ratio that for every 10 on-shore drilling efforts in the US only four are successful," said Robert W. Dean, CEO of ViaLogy. "Our hope is that as QuantumRD's successes grow it will earn a reputation as a must-have tool in the exploration industry."

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLC  

John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)  

Mark Percy +44 (0) 20-7107-8000

Broker to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLGUUGCCUPBUMQ
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.